OLD National Bancorp IN Has $1.02 Million Holdings in Astrazeneca Plc $AZN

OLD National Bancorp IN lessened its stake in shares of Astrazeneca Plc (NYSE:AZN) by 57.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,196 shares of the company’s stock after selling 7,061 shares during the quarter. OLD National Bancorp IN’s holdings in Astrazeneca were worth $1,025,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Bank of America Corp DE lifted its stake in shares of Astrazeneca by 4.7% in the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after buying an additional 1,461,786 shares during the last quarter. Fisher Asset Management LLC grew its stake in Astrazeneca by 2.1% in the 4th quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock valued at $3,791,051,000 after buying an additional 438,709 shares during the last quarter. Franklin Resources Inc. raised its holdings in Astrazeneca by 2.3% in the 4th quarter. Franklin Resources Inc. now owns 20,157,744 shares of the company’s stock worth $3,537,684,000 after acquiring an additional 445,014 shares during the period. Morgan Stanley raised its holdings in Astrazeneca by 3.2% in the 4th quarter. Morgan Stanley now owns 13,878,726 shares of the company’s stock worth $2,435,716,000 after acquiring an additional 432,939 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Astrazeneca by 9.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock worth $521,517,000 after acquiring an additional 582,183 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on AZN. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Finally, DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Astrazeneca presently has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Performance

Shares of NYSE AZN opened at $188.58 on Friday. The firm has a market capitalization of $292.47 billion, a price-to-earnings ratio of 28.32, a PEG ratio of 1.64 and a beta of 0.25. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The business has a fifty day simple moving average of $184.66 and a 200 day simple moving average of $187.05. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Sell-side analysts expect that Astrazeneca Plc will post 9.39 EPS for the current year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.